Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

84 results about "Cell-free system" patented technology

A cell-free system is an in vitro tool widely used to study biological reactions that happen within cells apart from a full cell system, thus reducing the complex interactions typically found when working in a whole cell. Subcellular fractions can be isolated by ultracentrifugation to provide molecular machinery that can be used in reactions in the absence of many of the other cellular components. Eukaryotic and prokaryotic cell internals have been used for creation of these simplified environments. These systems have enabled cell-free synthetic biology to emerge, providing control over what reaction is being examined, as well as its yield, and lessening the considerations otherwise invoked when working with more sensitive live cells.

Eukaryotic use of non-chimeric mutational vectors

The invention is based on the reaction of Duplex Mutational Vector in a cell-free system containing a cytoplasmic cell extract and a test plasmid. The reaction specifically converts a mutant kanr gene to recover the resistant phenotype in transformed MutS, RecA deficient bacteria. Using this system a type of Duplex Mutational Vector termed a Non-Chimeric Mutational Vector, having no RNA:DNA hybrid-duplex is shown to be an effective substrate for eukaryotic enzymes. The invention concerns the use of Non-Chimeric Mutational Vectors protected from 3' exonuclease attack in eukaryotic cells. Such protection can be conferred by replacement of a tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2'-O-methyl-uridine, to link the two strands of the recombinagenic oligonucleobase.
Owner:VALIGEN US +1

Infrared thermography

The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.
Owner:SMITHKLINE BECKMAN CORP

Eukaryotic use of improved chimeric mutational vectors

The invention is based on the reaction of recombinagenic oligonucleotides in a cell-free system containing a cytoplasmic cell extract and a test duplex DNA on a plasmid. The reaction specifically converts a mutant kanr gene to recover the resistant phenotype in transformed MutS, RecA deficient bacteria and allows for the rapid and quantitative comparison of recombinagenic oligonucleobases. Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacement of a tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2'-O-methyl-uridine, to link the two strands of the Duplex Mutational Vector and removal of the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern a reaction mixture containing a recombinagenic oligonucleobase, a cell-free enzyme mixture and a duplex DNA containing a target sequence. In yet an alternative embodiment, the invention concerns the use of such mixture to test improvements in recombinagenic oligonucleobases, as well as to test the effects of compounds on the activity of the cell-free enzyme mixture and also to make specific changes in the target DNA sequence.
Owner:CIBUS

ARMS-qPCR (Allele Refractory Mutation System-quantitative Polymerase Chain Reaction) detection kit for KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) gene mutation subtype and detection method

The invention relates to the field of molecular biology and aims to provide an ARMS-qPCR (Allele Refractory Mutation System-quantitative Polymerase Chain Reaction) detection kit for KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) gene mutation subtype and a detection method. The kit comprises a qPCR hybrid reaction solution, a locked nucleic acid retardant probe, a reference primer, an ARMS primer and a positive control sample, wherein the qPCR hybrid reaction solution comprises a PCR buffer solution, dNTPs (Deoxynucleotide Triphosphates), MgCl2, GoldStarbest Taq enzyme, a universal PCR reverse primer and a universal TaqMan probe. The kit provided by the invention can be used for rapidly and accurately detecting specific locus mutation of KRAS genes in various cancer tissues with high sensitivity, has high sensitivity, and can be used for detecting genome DNA with various tissue origins, specially free DNA segments adopting cell-free systems, such as blood serum and blood plasma, orother body fluid origins, wherein the genome DNA is derived from cell systems. Compared with direct sequencing and other mutation detection technologies, the kit and the detection method thereof havethe advantages of strong specificity, high sensitivity, simplicity and rapidness in operation, high throughput, safety, definiteness and objectivity in result identification and the like for detecting the KRAS gene mutation.
Owner:ZHEJIANG UNIV

Infrared thermography

InactiveUS6983753B1Inhibit thermogenesisFacilitates production of heatSurgeryDiagnostic recording/measuringDiseasePresent method
The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.
Owner:GLAXO WELLCOME INC

Methods for producing protein domains and analyzing three dimensional structures of proteins by using said domains

There is provided a method for producing a soluble protein domain comprising: (a) preparing two or more DNA fragments by partially digesting a DNA coding for a protein; (b) expressing the protein which is coded on each of said DNA fragments, as a fusion protein with a functional protein; (c) selecting the fusion protein exhibiting said function among two or more fusion proteins synthesized in step (b); and, (d) synthesizing the soluble protein domain which is coded on said DNA fragment in a cell-free system, wherein said soluble protein domain is included in said fusion protein selected in step (c). By using this method, it can be easy and efficient to analyze the three dimensional structure of proteins of many clones.
Owner:RIKEN

Methods of RNA and protein synthesis

The present invention relates to methods for RNA and / or protein synthesis using in vitro or in vivo expression systems. More specifically, the present invention provides a method for RNA and / or protein synthesis characterized in that the concentration of alpha subunit of RNA polymerase, but not of other subunits, is increased in the cellular or cell-free system, comparing to its natural concentration existing in the cellular or cell-free system.
Owner:UNIV DE NANTES

Cell-free preparation of carbapenems

Provided herein are cell-free systems for generating carbapenems, e.g., a compound of the Formula (I):or salts thereof; wherein , R1, R2, R3, R4, R5, and R6 are defined herein. Also provided are pharmaceutical compositions comprising a compound generated by the inventive cell-free system, and use of these compounds and compositions for the treatment of bacterial infections.
Owner:GREENLIGHT BIOSCIENCES INC

Infrared thermography

The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.
Owner:LENHARD JAMES +1

Compositions and methods for regulating mRNA transcription and translation

The invention relates to compositions, specifically novel nucleic acid constructs encoding a cardiovirus 2A polypeptide operably linked to suitable promoters. Also, disclosed are methods whereby the nucleic acid constructs are introduced into cells or cell free systems to regulate cellular mRNA transcription and cap-dependent or internal ribosomal entry site (IRES)-dependent mRNA translation.
Owner:WISCONSIN ALUMNI RES FOUND

Cell-free system for synthesis of proteins derived from cultured mammalian cells

Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and / or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.
Owner:RIKEN

DNA mini-circles and uses thereof

Methods and kits for generating circular nucleic acids in a cell-free system, and uses for the generated circular nucleic acids are provided. The methods comprise in vitro amplification of a nucleic acid template comprising a recombination site to produce tandem repeat nucleic acid sequence, and employ a recombination protein to generate the circular nucleic acids from the tandem repeat nucleic acid sequence.
Owner:GLOBAL LIFE SCI SOLUTIONS OPERATIONS UK LTD

Enzymes, cells and methods for site specific recombination at asymmetric sites

The present invention relates to enzymes, compositions and methods for catalyzing asymmetric recombination of non-palindromic recombination sites in a cell free system, in isolated cells or in living organisms. The enzymes and methods of the invention are suitable for mediating specific recombinations between DNA sequences comprising specific recombination sites without being limited to strict palindromic symmetry within each recombination site.
Owner:THE STATE OF ISRAEL MINIST OF AGRI & RURAL DEV AGRI RES ORG ARO VOLCANI CENT +1

Method catalytically synthesizing (S)-N, N-dimethyl-3-hydroxy-(2-thiofuran)-1-propylamine((S)-DHTP) by aldehyde ketone reductase recombinant strain crude enzyme system

The invention discloses a method catalytically synthesizing (S)-N, N-dimethyl-3-hydroxy-(2-thiofuran)-1-propylamine((S)-DHTP) by aldehyde ketone reductase recombinant strain crude enzyme system, and belongs to the technical field of biological catalysis asymmetric conversion. An auxiliary substrate and original bulk coenzyme NADP<+> are added in the recombinant strain crude enzyme system to accelerate regeneration cycle of coenzyme NADPH in the system; the reaction substrate is N, N-dimethyl-3-ketone-(2-thiophene)-1-propylamine (DTKP); the recombinant strain is E. coliBL21(DE3)(pETCPAR4); aldehyde ketone reducing enzyme gene cpar4 comes from Candida parapsilosis; the gene coded aldehyde ketone reducing enzyme gene CPAR4 catalytically and asymmetrically reduces the DKTP into (S)-DHTP. The method utilizes the cell-free system to conduct catalytic reaction; coupling enzyme required by regeneration of the coenzyme is not extra added in the reaction system; direct acting efficiency of the enzyme and the substrate is improved; reaction time is shortened; the conversion effect is relatively good.
Owner:JIANGNAN UNIV

Fermentation systems

The present disclosure pertains to novel cell cultivation and cell and / or cell-derived product production processes that have advantages over currently existing fermentation strategies. The processes and methods according to the present disclosure may be used for an efficient supply of highly viable and metabolically active eukaryotic cells for transient production platforms, as an alternative production process with advantages over currently applied processes (batch, fed-batch or perfusion strategies) and for generating metabolically highly active biomass for subsequent use for transient expression systems or infection by a virus or pseudovirus or in cell-free systems.
Owner:FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV

Prokaryote-based cell-free system for the synthesis of glycoproteins

The present invention is directed to a cell-free system for producing a glycosylated protein. This system comprises an isolated oligosaccharyltransferase capable of transferring a glycan from a lipid carrier molecule to a glycoprotein target, one or more isolated glycans, where each glycan is linked to a lipid carrier molecule, and a glycoprotein target comprising one or more glycan acceptor amino acid residues or a nucleic acid molecule encoding said glycoprotein target. The present invention further relates to kits and methods for producing a glycosylated protein in this cell-free system.
Owner:CORNELL UNIVERSITY

Method for synthesizing cadmium selenide quantum dots based on amino acid and polypeptide

The invention discloses a method of synthesizing CdSe quantum dots with Amino acid and polypeptide, comprising the following steps: A, preparing cell-free system of selenium-containing amino acid; B, preparing Cd-glutathione; C, synthesizing CdSe quantum dots. The invention is provided with a simple technology and mild reaction conditions. As no organometallic compounds are included in the preparation, the protection from the inert gas is not needed. The production is safe and low in cost, helpful to the industrial synthesis of the nano-particles (including quantum dots).
Owner:WUHAN UNIV

Cell-free system for synthesis of proteins derived from cultured mammalian cells

Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and / or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.
Owner:RIKEN

Method of replicating or amplifying circular DNA

Provided is a method capable of replicating or amplifying circular DNA, and particularly, long-chain circular DNA, in a cell-free system. Specifically, provided is a method for suppressing generation of a DNA multimer as a by-product, when circular DNA having a replication origin sequence (origin of chromosome (oriC)) is replicated or amplified by using the following enzyme groups:(1) a first enzyme group that catalyzes replication of circular DNA;(2) a second enzyme group that catalyzes an Okazaki fragment maturation and synthesizes two sister circular DNAs constituting a catenane; and(3) a third enzyme group that catalyzes a separation of two sister circular DNAs.Moreover, also provided is a method comprising introducing oriC into circular DNA by using a transposon.
Owner:MODERNA ENZYMATICS CO LTD

Method for carrying out gene mutation detection on cell-free system by HRM technology

The invention discloses a method for carrying out gene mutation detection on a cell-free system by an HRM technology. The invention is characterized in that the method comprises the following steps: (1) designing and selecting a plurality of primer pairs containing continuous nucleotide sequences formed by at least 15 continuous nucleotides in the targeted region of a target gene; (2) extracting DNA from the cell-free system, and utilizing the plurality of primer pairs screened in advance to carry out specific amplification on the targeted sequence of the target gene; and (3) carrying out mutational site detection on the amplified gene sequence according to a high-resolution fusion curve method. The method provides more extensive selectable samples for the detection and the analysis on related diseases by the cell-free system application technical research and obviously reduces invasive harm of the diseases on patients.
Owner:JIANGSU MICRODIAG BIOMEDICINE TECH CO LTD

Methods and compositions that affect melanogenesis

The invention provides methods of screening for compounds that affect melanogenesis and the function of P protein in organisms, cells, or cell-free systems. The invention further relates to pharmacologic and cosmetic uses of methods of inhibiting melanogenesis, methods of activating melanogenesis, and compounds and pharmacologic compositions useful for the inhibition or activation of melanogenesis and, therefore, for lightening or darkening the pigmentation of cells and tissue, i.e., skin.
Owner:NEW YORK UNIV

Preparation method of insect cell extract solution for cell-free protein synthesis, the insect cell extract solution and cell-free synthesis method of protein using the insect cell extract solution

The present invention provides a preparation method of an insect cell extract solution for cell-free protein synthesis, the insect cell extract solution, a protein synthesis method in a cell-free system, which uses the insect cell extract solution, and a kit for cell-free protein synthesis containing the insect cell extract solution. The extract solution is easily prepared by the method of the present invention and can synthesize a higher amount of protein than by extract solutions prepared by conventional methods.
Owner:SHIMADZU CORP

Method for producing HIV-1 gp41 recombinant antigen by means of Escherichia coli cell-free system

InactiveCN105039379AImprove soluble expression efficiencyAvoid damageVirus peptidesPeptide preparation methodsAntigenEscherichia coli
The invention discloses a method for producing an HIV-1 gp41 recombinant antigen by means of an Escherichia coli cell-free system. The method comprises the steps that an HIV-1 gp41 gene is cloned on a pIVEX2.4c plasmid to obtain a recombinant vector pIVEX2.4c-gp41; the recombinant vector pIVEX2.4c-gp41 is placed into the Escherichia coli cell-free system containing a decontamination agent for expression, and finally affinity chromatography purification is utilized for obtaining the HIV-1 gp41 protein. According to the HIV-1 gp41 protein produced through the HIV-1 gp41 protein, the decontamination agent is added into the reaction system to improve the solubility of the HIV-1 gp41, and the affinity chromatography purification is utilized for obtaining the target protein. The method can effectively improve the production capacity of the HIV-1 gp41 recombinant antigen and is of great significance in producing a series of HIV recombinant antigens by means of the Escherichia coli cell-free system.
Owner:ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products